Loading
companiesCompany
K36 Therapeutics
K36 Therapeutics makes pills that block an enzyme called NSD2 (also known as MMSET), which is overactive in about one in five multiple myeloma cases because of a chromosome swap. It is also testing the approach in prostate cancer.
Overview
K36 Therapeutics is a Cambridge, Massachusetts clinical-stage company and the first to target the histone methyltransferase NSD2 (MMSET/WHSC1). Gintemetostat (KTX-1001) is a first-in-class, oral, selective catalytic NSD2 inhibitor in the K36-MMSET-001 trial in relapsed or refractory multiple myeloma with the t(4;14) translocation; the company reports target engagement, an encouraging safety profile and clinical activity in heavily pretreated patients, with expansion cohorts combining it with carfilzomib, mezigdomide or pomalidomide. KTX-2001, a second oral NSD2 inhibitor, is in the K36-STRIKE-001 trial in metastatic castration-resistant prostate cancer alone and with darolutamide. K36 launched in December 2021 with a 30 million US dollar Series A co-led by F-Prime Capital and Atlas Venture, and raised a 70 million US dollar Series B in June 2023 led by Nextech Invest with Bristol Myers Squibb participating.
Headquarters
Cambridge, MA, US
Funding
All startupsStartup
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by Nextech Invest with participation from Bristol Myers Squibb and existing investors | 2023 | $70M | prnewswire.com |
| Series A · Co-led by F-Prime Capital and Atlas Venture with Eight Roads Ventures | 2021 | $30M | prnewswire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- No SEC Form D filings were found under the company name. Founding year not sourced.
Similar pages
- TrialMEVPRO-1
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- PersonChristopher R. Vakoc
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- TechnologyEpigenetic editing (durable gene silencing)
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
- PersonWilliam G. Nelson
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- CompanyProxygen
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Prostate cancer.
- TreatmentPanobinostat
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Multiple myeloma.
- CompanyFoghorn Therapeutics
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Multiple myeloma, Prostate cancer.
- PersonStephen B. Baylin
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).